What is HC Wainwright’s Estimate for RANI Q1 Earnings?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Rani Therapeutics in a research note issued on Friday, March 27th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of ($0.06) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Rani Therapeutics’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Rani Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2030 earnings at ($0.30) EPS.

Rani Therapeutics (NASDAQ:RANI) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.04). The firm had revenue of $1.46 million during the quarter, compared to the consensus estimate of $5.00 million.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Rani Therapeutics in a report on Friday. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Rani Therapeutics Stock Performance

Shares of NASDAQ:RANI opened at $0.73 on Monday. The stock has a 50-day simple moving average of $1.25 and a 200-day simple moving average of $1.32. The stock has a market capitalization of $89.29 million, a P/E ratio of -1.25 and a beta of 0.39. Rani Therapeutics has a 1 year low of $0.39 and a 1 year high of $3.87.

Institutional Investors Weigh In On Rani Therapeutics

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in Rani Therapeutics during the 4th quarter valued at $69,000. Millennium Management LLC bought a new position in shares of Rani Therapeutics during the fourth quarter valued at approximately $220,000. Bridgeway Capital Management LLC bought a new stake in Rani Therapeutics in the fourth quarter valued at $155,000. 683 Capital Management LLC acquired a new stake in shares of Rani Therapeutics in the 4th quarter worth approximately $658,000. Finally, RA Capital Management L.P. bought a new position in shares of Rani Therapeutics in the fourth quarter valued at $11,475,000. 30.19% of the stock is currently owned by hedge funds and other institutional investors.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.